STOCK TITAN

NanoViricides (NNVC) Stock News, Jul 2023-Feb 2024

NNVC NYSE

NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.

Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.80%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.70%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
partnership conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
none

FAQ

What is the current stock price of NanoViricides (NNVC)?

NanoViricides (NNVC) last closed at $1.16.

What is the market cap of NanoViricides (NNVC)?

The market cap of NanoViricides (NNVC) is approximately $29.6M.